Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cytarabine + Idarubicin + Volasertib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
Idarubicin | Idamycin | Idarubicin Hcl | Chemotherapy - Anthracycline 13 | Idamycin (idarubicin) is an anthracycline that inhibits DNA replication thereby preventing RNA and protein synthesis, which may lead to tumor growth inhibition (PMID: 2192943). Idamycin (idarubicin) in combination with other approved drugs is FDA-approved for acute myelogenous leukemia (FDA.gov). |
Volasertib | BI 6727|BI6727|BI-6727 | PLK1 Inhibitor 18 | Volasertib (BI 6727) inhibits polo-like kinase I (PLK1), resulting in cell cycle arrest and apoptosis in tumor cells (PMID: 27330107, PMID: 30782614, PMID: 32728610). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02527174 | Phase I | Cytarabine + Idarubicin + Volasertib | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC) | Withdrawn | CAN | 0 |
NCT02905994 | Phase I | Cytarabine + Idarubicin + Volasertib | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | Withdrawn | USA | 0 |